Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553317 · ClinicalTrials.gov registry record · Phase 3
Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
A Phase 3 study, sponsored by Ablynx, a Sanofi company.
- Completed
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
NCT02553317 is a Phase 3 study that has completed, run by Ablynx, a Sanofi company. The registered enrollment target is 145 participants.
The verdict
NCT02553317, a Phase 3 study, has completed, sponsored by Ablynx, a Sanofi company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
Study Summary
The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Caplacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02553317
The ClinicalTrials.gov registry entry for NCT02553317 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ablynx, a Sanofi company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02553317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02553317 about?
NCT02553317 is a clinical study titled "Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura". The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis
What is the current status of trial NCT02553317?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2015-11. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02553317?
The interventions under investigation include: Placebo (BIOLOGICAL), Caplacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02553317?
This trial is sponsored by Ablynx, a Sanofi company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.